According to the DRHP, the proposed IPO of Hyderabad company is a combination of the sale of equity shares (OFS) of 1.27 crore equity shares by new issues and sales shareholders of the proposed IPO equity shares.
As part of the OFS, promoter cellholders include Investocorp Private Equity Fund II, Healthcare Parent Limited, Investorp Growth Opportunity Fund and Adoras Investment Holdings PTE. Limited and other sales shareholders include Investorp India Private Equity Opportunity Limited, International Finance Corporation, 360 A special opportunities – range 9 and 360 funds – range 10.
The company is in consultation with Running Lead Managers (BRLMS) and before filing Red Harring Prospectus (RHP) with ROC, Rs. Pre-IPOs up to 70.6 crore can consider placement. If pre-IPO placement is carried out, the fresh problem will be reduced to the extent of such pre-IPO placement.
About Nephrocare Health Services
Known for its brand nephroplus, the company claims to be the fifth -seeded globally in terms of the number of treatments being done in FY 2025, citing Asia’s largest dialysis services provider and F&S report. Included in 2009, nephroplus has 447 clinics in 21 states and 269 cities in 4 union regions. It serves more than 33,3 patients globally, on an annual basis, and is part of the market in India’s organized market (in terms of treatment number).
It has also expanded its international steps to include the Philippines (Clin Clinics), Uzbekistan (Clin Clinics), Nepal (Clin Clinics) and recently entered the Middle East market by the state of Saudi Arabia.
Vikram Wupala, BVP (Basemer Venture Partners) Trust, Adoras Investment Holdings PT. Ltd., Healthcare Parent Limited (HPL), Investocorp Private Equity Fund II (IPEF II) and Investorp Growth Tak Fund (IGOF) are promoters.
The use of Nephrocare Health Services moves forward
Nefroplus has to open a new dialysis clinics in India for Rs. It has proposed to use a net income of new issues towards capital expenditure of Rs 129.1 crore. It will use Rs 136 crore for some borrowed payment or scheduled payment by the company and rest on general corporate purposes.
In FY22, Nephroplace costs Rs. 755.8 crore and Rs. 67 crores.
Currently, kidney disease is the third rapid cause of death globally, and diabetes and hypertension have been recognized as two leading drivers of chronic kidney disease (CKD). Fast urbanization and lifestyle changes have contributed further to the increased CKD’s increased incidence.
ICICI Securities Limited, Ambit Private Limited, IIFL Capital Services Limited and Nomura Financial Advisory and Securities (India) Private Limited are lead managers on the issue.
(Connection: The recommendations, suggestions, opinions and opinions provided by experts have their own. This does not represent opinions of economic time)
(Now you can subscribe to our Etmarkets WhatsApp channel)
